Market Closed -
Nasdaq
21:30:00 24/05/2024 BST
|
5-day change
|
1st Jan Change
|
0.4112
USD
|
-20.92%
|
|
+62.53%
|
+48.50%
|
Fiscal Period: December |
2023
|
---|
Capitalization
1 |
5.826
|
Enterprise Value (EV)
1 |
5.216
|
P/E ratio
|
-0.48
x
|
Yield
|
-
|
Capitalization / Revenue
|
7,964,310
x
|
EV / Revenue
|
7,129,952
x
|
EV / EBITDA
|
-644,404
x
|
EV / FCF
|
-1,827,264
x
|
FCF Yield
|
-0%
|
Price to Book
|
7.66
x
|
Nbr of stocks (in thousands)
|
21,040
|
Reference price
2 |
0.2769
|
Announcement Date
|
01/04/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
0.008939
|
0.7315
|
EBITDA
|
-
|
-1.988
|
-8.094
|
EBIT
1 |
-0.0701
|
-1.992
|
-8.118
|
Operating Margin
|
-
|
-22,279.7%
|
-1,109.84%
|
Earnings before Tax (EBT)
1 |
-0.0708
|
-1.998
|
-9.212
|
Net income
1 |
-0.0708
|
-1.998
|
-9.212
|
Net margin
|
-
|
-22,352.11%
|
-1,259.4%
|
EPS
|
-
|
-0.1850
|
-0.5717
|
Free Cash Flow
|
-
|
-0.4892
|
-2.854
|
FCF margin
|
-
|
-5,472.91%
|
-390.2%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
26/09/22
|
21/02/23
|
01/04/24
|
Fiscal Period: December |
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.02
|
-
|
-
|
Net Cash position
1 |
-
|
0.33
|
0.61
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-0.49
|
-2.85
|
ROE (net income / shareholders' equity)
|
-
|
-669%
|
-1,327%
|
ROA (Net income/ Total Assets)
|
-
|
-243%
|
-494%
|
Assets
1 |
-
|
0.8233
|
1.865
|
Book Value Per Share
2 |
-0
|
0.0500
|
0.0400
|
Cash Flow per Share
2 |
0
|
0.0500
|
0.0300
|
Capex
|
-
|
0.04
|
0
|
Capex / Sales
|
-
|
482.18%
|
0.48%
|
Announcement Date
|
26/09/22
|
21/02/23
|
01/04/24
|
|
1st Jan change
|
Capi.
|
---|
| +48.50% | 10.21M | | +89.66% | 3.63B | | -46.73% | 1.95B | | +78.57% | 584M | | +12.60% | 485M | | -26.62% | 91.48M |
Telemedicine Services
|